Journal: Cancer immunology research

Article Title: Combined anti-VEGF and anti–CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes

doi: 10.1158/2326-6066.CIR-16-0385

Figure Lengend Snippet: Anti-Gal-1 antibodies isolated from an Ipi-Bev-treated patient abrogate Gal-1 binding to CD45. Anti-Gal-1 antibodies were affinity purified from plasma. Biotinylated HAS-Gal-1 (250 ng/ml) was incubated with a commercial anti-Gal-1 polyclonal antibody (Gal-1 Ab) or control antibody (10 μg/ml), enriched endogenous Gal-1 antibodies (Gal-1 Ig) or normal human IgG (1.98 μg/ml) prior to incubation with coated CD45. The binding of HAS-Gal-1 to CD45 was detected with streptavidin-HRP. Sucrose and lactose were added to the reaction at 5 mM. Data are presented as Mean ± SD of 3 experiments.

Article Snippet: Recombinant human CD45 (R&D Systems) was coated onto 96-well plates (25 ng/well) at 4°C overnight.

Techniques: Isolation, Binding Assay, Affinity Purification, Clinical Proteomics, Incubation, Control

Journal: EBioMedicine

Article Title: Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour

doi: 10.1016/j.ebiom.2020.102850

Figure Lengend Snippet: Kaplan-Meier analysis of RFS according to individual TIL populations in the TC. (a) CD3 + TC. (b) CD8 + TC. (c) CD45RO + TC. (d) Foxp3 + TC. (e) CD4 + TC. (f) NKp46 + TC. (g) CD20 + TC.

Article Snippet: Then, sections were incubated with primary antibodies against CD3 (Ventana, 790–4341; ready-to-use), CD8 (Dako, M7103; 1:100 dilution), CD45RO (Origene, TA807197; 1:100 dilution), CD4 (Abcam, ab213215; 1:300 dilution), Foxp3 (Abcam, ab22510; 1:200 dilution), NKp46 (Abcam, ab214468; 1:500 dilution), CD20 (Abcam, ab27093; 1:200 dilution), programmed death-1(PD-1) (Cell signaling Technology, 43,248; 1:50 dilution), and programmed death-ligand 1 (PD-L1) (Dako, M3653; 1:50 dilution) at 4 °C overnight.

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Jianpi Yangzheng Xiaozheng decoction alleviates gastric cancer progression via suppressing exosomal PD-L1

doi: 10.3389/fphar.2023.1159829

Figure Lengend Snippet: JPYZXZ reduced the number of MDSCs in tumor bearing mice. (A,B) Percentage of MDSCs (CD45 + CD11b+Gr1+) in blood determined using flow cytometry. (C,D) Percentage of MDSCs (CD45 + CD11b+Gr1+) in tumors determined using flow cytometry. (E) Immunofluorescence staining for DAPI (nucleus), CD11b, Gr-1, and PD-L1 in tumor tissue sections from the xenograft tumor model. Data are represented as the mean ± SEM, n = 5 mice or n = 3 independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: The single-cell suspensions (1 × 10 7 cells/mL) were stained with fluorochrome-coupled antibodies AF488-CD45 (Elabscience, E-AB-F1136L), PE/Dazzle™594-CD11b (BioLegend, 101256), and APC-Gr-1 (BioLegend, 108412) for 30 min at 4°C.

Techniques: Flow Cytometry, Immunofluorescence, Staining